Mylan sales and revenue up while EpiPen becomes its first $1 billion-selling product

3 March 2015

US generic drugmaker Mylan (Nasdaq: MYL) has reported strong growth throughout the company for the fourth quarter and 2014 full year.

The company reported quarterly total revenue of $2.08 billion, an 18% quarter-on-quarter growth, while full year sales stood at $7.72 billion, up 13% on 2013. The $2.08 billion in revenue, however, missed analysts' prediction of $2.09 billion.

Earnings before interest, tax, depreciation and amortization were up 32% for the quarter, now $682 million, with annual figures at $2.37 billion, up 21% on last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK